Clinical trials
Completed Phase 2 Gastrointestinal Stromal Tumors trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
66 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 3 |
| 2001 | 1 |
| 2002 | 4 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 5 |
| 2006 | 4 |
| 2007 | 2 |
| 2008 | 8 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 4 |
| 2012 | 4 |
| 2013 | 3 |
| 2014 | 4 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 66 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 12 |
| Asan Medical Center | 7 |
| National Cancer Institute (NCI) | 7 |
| European Organisation for Research and Treatment of Cancer - EORTC | 3 |
| Astex Pharmaceuticals, Inc. | 2 |
| Pfizer | 2 |
| Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | 2 |
| Zai Lab (Shanghai) Co., Ltd. | 2 |
| AEterna Zentaris | 1 |
| Adam Burgoyne, MD, PhD | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Gastrointestinal Stromal Tumors | 66 |
| Sarcoma | 12 |
| Leiomyosarcoma | 5 |
| Neoplasms | 5 |
| Fibrosarcoma | 4 |
| Histiocytoma, Malignant Fibrous | 4 |
| Liposarcoma | 4 |
| Neoplasm Metastasis | 4 |
| Neurofibrosarcoma | 4 |
| Ovarian Neoplasms | 4 |
Trials
Showing 1 to 25 of 66. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.